Recent Updates
Recently added Catalysts
TELO Positive Sentiment

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Telomir Pharmaceuticals has announced a peer-reviewed publication showcasing the effectiveness of Telomir-Zn in suppressing tumor growth in models of triple-negative breast cancer (TNBC) and prostate cancer. The study highlights the compound's ability to selectively modulate intracellular iron and copper levels, suggesting a novel approach to cancer treatment. This publication adds credibility to Telomir's ongoing research efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Peer-reviewed publication validates Telomir-Zn's efficacy.
  • Demonstrated tumor growth suppression in TNBC and prostate cancer models.
  • Potential for new therapeutic options targeting cancer metabolism.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
9.9%
average across 2 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
Zn-Telomir
Phase 1 · Triple-Negative Breast Cancer (TNBC)

Full Press Release Details

MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of preclinical data of Telomir-Zn suppressing tumor growth in prostate and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper. The manuscript, titled “Telomir-Zn Modulates Intr…
You can read the full content here
The post Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models appeared first on Telomir Pharmaceuticals, Inc. (TELO) .

Frequently Asked Questions

What is Telomir-Zn?

Telomir-Zn is a small-molecule therapeutic developed by Telomir Pharmaceuticals targeting cancer.

What types of cancer does Telomir-Zn target?

Telomir-Zn targets triple-negative breast cancer (TNBC) and prostate cancer.

What did the peer-reviewed publication demonstrate?

The publication demonstrated that Telomir-Zn suppresses tumor growth in cancer models.

How does Telomir-Zn work?

Telomir-Zn works by selectively modulating intracellular iron and copper levels.

ShareAdd on Google
Tags: TELO Viatris Investor Conferences Healthcare Telomir Pharmaceuticals Telomir-Zn triple-negative breast cancer prostate cancer tumor growth suppression
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$6M liquidity · $1M/mo burn
~7 mo
Medium dilution risk
Lead asset
Zn-TelomirPhase 1
Triple-Negative Breast Cancer (TNBC) →

Catalyst track record

+37%
best trade around TELO's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TELO.

See every catalyst's timing & PoA →